Leerink Partners analyst Joseph Schwartz initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Outperform rating and announces Price Target of $6.
Leerink Partners Initiates Coverage On Regulus Therapeutics With Outperform Rating, Announces Price Target of $6
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.